Sturge–Weber syndrome (SWS)
Introduction
SWS is a rare, sporadic neurocutaneous disorder characterized by vascular malformations involving the skin, brain, and eyes. It is a phakomatoses characterized by a facial capillary malformation (port-wine stain), leptomeningeal angiomatosis, and ocular abnormalities, including glaucoma. The condition is named after William Allen Sturge and Frederick Parkes Weber, who contributed to its early clinical description. The clinical presentation is highly variable, depending on the extent and location of vascular involvement.
Genetics
The genetic basis of Sturge–Weber syndrome differs fundamentally from that of other neurocutaneous disorders, as it is caused by a somatic activating mutation in the GNAQ gene (G Protein Subunit Alpha Q) located on chromosome 9q21. This mutation occurs in the postzygotic phase and leads to partial mosaicism, which accounts for the segmental distribution of vascular lesions. This gene encodes a G protein subunit that participates in intracellular signaling pathways that regulate vascular development. The mutation results in persistent activation of downstream signaling pathways, particularly the MAPK (mitogen-activated protein kinase) pathway, contributing to abnormal vascular formation and persistence.
Epidemiology
Sturge–Weber syndrome has an estimated incidence of 1 in 20,000–50,000 live births. It is considered a rare disorder and affects males and females equally, and occurs worldwide without known ethnic predilection. Most cases are sporadic, with no increased recurrence risk in families. The presence of a facial port-wine stain, particularly in the distribution of the ophthalmic branch of the trigeminal nerve (V1), is a key clinical marker associated with increased risk of intracranial involvement.
Pathophysiology
The pathophysiological mechanism of SWS is based on abnormal vascular development during embryogenesis. During early fetal life, a primitive vascular plexus surrounding the cephalic neural tube undergoes regression. In SWS, this regression fails and leads to persistent leptomeningeal capillary-venous malformations that commonly occur in the occipital and parietal lobes. These vascular anomalies lead to impaired venous drainage, chronic cerebral hypoperfusion, and subsequently progressive cortical injury. These cortical injuries include calcification, gliosis, and cortical atrophy.
Ocular involvement arises from similar vascular malformations affecting the choroid and episcleral vessels, contributing to increased intraocular pressure and glaucoma.
Clinical manifestations
The main clinical feature is a facial port-wine stain (nevus flammeus), which is usually unilateral and involves the forehead and upper eyelid. Neurological manifestations often begin in infancy and include different types of seizures, which are often refractory. Recurrent seizures and chronic focal hypoperfusion in the brain result in other neurological symptoms, including hemiparesis, visual field defects, and cognitive impairment. Developmental delay and intellectual disability are common, particularly in individuals with early-onset and refractory epilepsy. Ocular manifestations include glaucoma, which may be present at birth or develop later, and choroidal hemangiomas, which can impair vision.
Diagnosis
Diagnosis of SWS is based on clinical features and neuroimaging. Magnetic resonance imaging (MRI) with contrast is the modality of choice and typically demonstrates leptomeningeal enhancement, cortical atrophy, and characteristic “tram-track” calcifications, although the latter are more clearly seen on computed tomography (CT). Ophthalmological evaluation is essential for detecting and monitoring glaucoma. The diagnosis may also be supported by identification of a GNAQ mutation in affected tissue, although genetic testing is not routinely required in typical cases. Early identification is important for surveillance and management of neurological and ocular complications.
Treatment
Management of Sturge–Weber syndrome is entirely symptomatic and requires a multidisciplinary approach. Seizure control is crucial and always requires antiepileptic medications. In refractory epilepsy, surgical interventions such as focal resection of the vascular lesion or hemispherectomy may be indicated. Low-dose aspirin is sometimes used to reduce the risk of thrombosis and stroke-like episodes, although evidence is limited. Glaucoma requires prompt and ongoing ophthalmologic treatment, including medical therapy or surgery. Laser therapy (e.g., a pulsed-dye laser) can improve the cosmetic appearance of a port-wine stain. Developmental support, physiotherapy, and educational interventions are important for optimizing functional outcomes.
Prognosis
The prognosis of SWS varies widely and depends largely on the extent of brain involvement and the severity of epilepsy. Early-onset and therapy-resistant seizures are associated with more severe neurodevelopmental outcomes. Individuals with limited leptomeningeal lesions may have relatively mild symptoms and preserved cognitive function. Vision outcomes depend on the severity of glaucoma severity and its management, as well as choroidal involvement. Although SWS is a lifelong condition, early diagnosis and comprehensive management can significantly improve quality of life and reduce complications.
